Gatuzosiran
Based on 1 Customer Validation
Gatuzosiran (GSK4532990; ARO-HSD) is a GalNAc-conjugated siRNA that inhibits HSD17B13. Gatuzosiran downregulates HSD17B13 mRNA and protein levels. Gatuzosiran improves noninvasive biomarkers of liver function enzymes, liver fibrosis, and steatosis associated with metabolic dysfunction-associated steatohepatitis. Gatuzosiran can be used for research on metabolic dysfunction-associated steatohepatitis.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 98.89%
- No. CAS: 2409783-34-0
- Fòrmula: C493H653F11N163O311P43S7
- Peso molecular:15603.70
-
Almacenamiento:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Actividad biológica
Descripciòn
IC50 & Target
[1]|
HSD17B13 |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 2409783-34-0
-
Appearance Solid
-
Peso molecular 15603.70
-
Fòrmula C493H653F11N163O311P43S7
-
Color White to off-white
-
SMILES
[Gatuzosiran]
-
Synonyms
GSK4532990; ARO-HSD
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Gatuzosiran
- 2409783-34-0
- GSK4532990
- ARO-HSD
- GSK 4532990
- GSK-4532990
- Small Interfering RNA (siRNA)
- 17β-HSD
- 17beta-HSD
- 17β-hydroxysteroid dehydrogenases
- 17 beta-hydroxysteroid dehydrogenase
- GalNAc-conjugated siRNA
- HSD17B13 expression
- HSD17B13 mRNA
- hepatocytes
- metabolic dysfunction-associated steatohepatitis
- Inhibitor
- inhibitor
- inhibit